BURLINGTON, Mass., March 28 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies Inc. (Nasdaq: PMTI), a leading researcher and developer of
light- based systems for cosmetic treatments, announced today that it will
unveil its latest innovation in aesthetic laser technology at the 28th
annual conference of the American Society for Laser Medicine & Surgery
(ASLMS) in Kissimmee Florida, April 2-6. Palomar will display a new
platform called the Aspire(TM) aesthetic laser platform and Stylus(TM)
Sculpter laser-assisted liposuction handpiece in booth #507 in the ASLMS
exhibit hall. The Aspire platform will allow Palomar to offer solutions to
new procedures which are in high-demand including laser-assisted
liposuction. The Aspire platform will complement the broad range of
aesthetic applications offered by Palomar's flagship StarLux(R) 500 laser
and pulsed-light platform.
Traditional liposuction is one of the most commonly performed plastic
surgery procedures, according to the 2007 survey from the American Society
of Aesthetic Plastic Surgery. Laser-assisted liposuction holds out the
promise for a better technique due to the laser's ability to quickly and
selectively melt fat and heat surrounding tissue. Palomar's approach to
laser-assisted liposuction with the Aspire platform and Stylus Sculpter
handpiece is to utilize unique tip designs and selective and efficient
wavelengths for melting fat and providing the desired thermal effects on
surrounding tissue.
Chief Executive Officer Joseph P. Caruso commented, "The unveiling of
the Aspire platform and Stylus Sculpter handpiece is the culmination of
years of research directed to absorption of light by fat. Our system uses
optimal wavelengths to melt fat and provide the appropriate amount of heat
to the surrounding tissue. As with all Palomar products, the Aspire
platform is based on sound scientific principles developed and tested by
Palomar's research and development organization, which is preeminent in the
light-based aesthetic industry."
Mr. Caruso continued, "The Aspire platform is an ideal complement to
the StarLux platform for providing opportunities for even more treatment
modalities. With the new aesthetic procedures that will be possible with
Aspire, and the many popular treatments, including hair removal, skin
rejuvenation and skin resurfacing, available with the StarLux(R) 500,
practitioners will be able to offer a complete suite of the most-requested
aesthetic procedures."
The Aspire Platform and Stylus Sculpter liposuction laser-assisted
handpiece are pending FDA clearance and should be available for shipment in
the third quarter.
In addition to the introduction of the Aspire platform, the following
presentations at ASLMS are relevant to Palomar technology:
April 4, 2008
-- Randomized Study of Intense Pulsed Light and Pulsed Dye Laser in the
Treatment of Facial Telangiectasia. 2:24 pm - 2:29 pm (The Sun AB Room)
-- Long-Term Experience with Fixed Array 1540 Fractional Erbium Laser for
Acne Scars. 3:54 pm - 3:59 pm (The Sun AB Room)
-- Ablative Micro-Fractional Resurfacing: Time-Course Histology and
Clinical Correlations. 4:23 pm - 4:28 pm (The Sun AB Room)
-- Use of a Micro-Fractional 2940 NM Laser in the Treatment of Wrinkles
and Dyspigmentation. 5:12 pm - 5:17 pm (The Grapevine B Room)
April 5, 2008
-- Self Canalization of Laser Microbeam in Tissue as Fundamental Mechanism
of Fractional Skin Resurfacing. 4:51 pm - 4:58 pm (The Sun AB Room)
April 6, 2008
-- Deep Infrared Light for Skin Tightening Combined with 1540NM Fractional
Resurfacing -- Split-Face Study. 8:20 am - 8:25 am (The Sun AB Room)
About Palomar Medical Technologies Inc.: Palomar is a leading
researcher and developer of light-based systems for cosmetic treatments.
Palomar pioneered the optical hair removal field, when, in 1997, it
introduced the first high-powered laser hair removal system. Since then,
many of the major advances in light-based hair removal have been based on
Palomar technology. In December 2006, Palomar became the first company to
receive a 510(k) over-the- counter (OTC) clearance from the United States
Food and Drug Administration (FDA) for a new, patented, home use,
light-based hair removal device. OTC clearance allows the product to be
marketed and sold directly to consumers without a prescription. There are
now millions of light-based cosmetic procedures performed around the world
every year in physician offices, clinics, spas and salons. Palomar is
testing many new and exciting applications to further advance the hair
removal market and other cosmetic applications. Palomar is focused on
developing proprietary light-based technology for introduction to the mass
markets. Palomar has granted The Procter & Gamble Company a non-exclusive
License Agreement to certain patents, technology and FDA documents related
to the home-use, light-based hair removal field for women. In addition,
Palomar has an exclusive development and license agreement with Johnson &
Johnson Consumer Companies to develop and potentially commercialize
home-use, light-based devices for reducing or reshaping body fat including
cellulite, reducing the appearance of skin aging, and reducing or
preventing acne.
For more information on Palomar and its products, visit Palomar's
website at http://www.palomarmedical.com . To continue receiving the most
up-to-date information and latest news on Palomar as it happens, sign up to
receive automatic e-mail alerts by going to the Investor Relations' section
of the website.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are based on the Company's current expectations,
plans, intentions, beliefs or predictions. These forward-looking statements
are neither promises nor guarantees, but involve risk and uncertainties
that may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from such
forward-looking statements. These risk factors include, but are not limited
to, results of future operations, technological difficulties in developing
or introducing new products, the results of future research, lack of
product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties and government contracts, the impact of
competitive products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained for
future products and additional applications, the results of litigation,
including patent infringement lawsuits, difficulties in collecting
royalties, potential infringement of third-party intellectual property
rights, factors affecting the Company's future income and resulting ability
to utilize its NOLs, and/or other factors, which are detailed from time to
time in the Company's SEC reports, including the report on Form 10-K for
the year ended December 31, 2007 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these
forward- looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
Contacts: Kayla Castle
Investor Relations Manager
Palomar Medical Technologies, Inc.
781-993-2411
kcastle@palomarmedical.com
SOURCE Palomar Medical Technologies Inc.
 back to top
Related links:
http://www.palomarmedical.com
http://www.prnewswire.com/comp/107555.html /
CONTACT:
Kayla Castle, Investor Relations Manager of
Palomar Medical Technologies, Inc., +1-781-993-2411,
kcastle@palomarmedical.com
|
